Cancer Treat Rev. 2009 Jun;35(4):335-9. Epub 2009 Jan 7.

Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

Rivera F, López-Tarruella S, Vega-Villegas ME, Salcedo M.

Source

Medical Oncology Department, Marqués de Valdecilla University Hospital, Cantabria, Spain. oncrhf@humv.es

Abstract

The prognosis of advanced pancreatic adenocarcinoma is still poor nowadays. Gemcitabine in monotherapy (30-min infusion) has been the standard of treatment during the last decade, and many clinical trials have failed to demonstrate an improvement in overall survival (OS) with the addition of different drugs to gemcitabine, including cetuximab and bevacizumab. Nevertheless, some modest but interesting advances have been provided by combinations such as gemcitabine-erlotinib, gemcitabine-capecitabine and gemcitabine plus a platinum salt. In spite of this, survival results remain disappointing. Further research focused on new combinations, incorporating the new targeted therapies and identifying potential predictive factors of response are required to be able to offer effective tailored therapies to these patients.

PMID:: 19131170; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

LinkOut - more resources

Full Text Sources

Medical

Pancreatic Cancer - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. [J Clin Oncol. 2009]
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, et al. J Clin Oncol. 2009 Nov 20; 27(33):5513-8. Epub 2009 Oct 26.
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. [J Clin Oncol. 2005]
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, et al. J Clin Oncol. 2005 May 20; 23(15):3509-16.
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008. [JOP. 2008]
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Saif MW. JOP. 2008 Mar 8; 9(2):91-8. Epub 2008 Mar 8.
Review Novel advances in pancreatic cancer treatment. [Expert Rev Anticancer Ther. 2008]
Review Novel advances in pancreatic cancer treatment.
Vulfovich M, Rocha-Lima C. Expert Rev Anticancer Ther. 2008 Jun; 8(6):993-1002.
Review Cytotoxic therapy for advanced pancreatic adenocarcinoma. [Semin Oncol. 2007]
Review Cytotoxic therapy for advanced pancreatic adenocarcinoma.
O'Reilly EM, Abou-Alfa GK. Semin Oncol. 2007 Aug; 34(4):347-53.

See reviews... See all...

Cited by 12 PubMed Central articles

Adjuvant and neoadjuvant treatment in pancreatic cancer. [World J Gastroenterol. 2012]
Adjuvant and neoadjuvant treatment in pancreatic cancer.
Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. World J Gastroenterol. 2012 Apr 14; 18(14):1565-72.
Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. [PLoS One. 2011]
Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway.
Paron I, Berchtold S, Vörös J, Shamarla M, Erkan M, Höfler H, Esposito I. PLoS One. 2011; 6(6):e21684. Epub 2011 Jun 29.
Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells. [Mol Cancer. 2011]
Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells.
Nakashima M, Adachi S, Yasuda I, Yamauchi T, Kawaguchi J, Hanamatsu T, Yoshioka T, Okano Y, Hirose Y, Kozawa O, et al. Mol Cancer. 2011 Jul 3; 10:79. Epub 2011 Jul 3.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Treatment of advanced pancreatic cancer: from gemcitabine single agent to combin...
Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
Cancer Treat Rev. 2009 Jun ;35(4):335-9. Epub 2009 Jan 7 .

PubMed
HIV-associated vascular diseases: structural and functional changes, clinical im...
HIV-associated vascular diseases: structural and functional changes, clinical implications.
Int J Cardiol. 2009 Apr 17 ;133(3):293-306. Epub 2009 Jan 7 .

PubMed
Application of appropriateness criteria in outpatient transthoracic echocardiogr...
Application of appropriateness criteria in outpatient transthoracic echocardiography.
J Am Soc Echocardiogr. 2009 Jan ;22(1):53-9.

PubMed
Role of MRI of the breast in the evaluation of the symptomatic patient.
Role of MRI of the breast in the evaluation of the symptomatic patient.
Curr Opin Obstet Gynecol. 2009 Feb ;21(1):74-9.

PubMed
Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spo...
Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer.
J Cell Biochem. 2009 Feb 15 ;106(3):491-505.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 12 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information